Archives — June 2017 back to current month (5)
Laidlaw & Company initiated coverage with a Buy rating and target price of $18 on a company that is repurposing an approved cannabinoid to fulfill unmet medical needs.
A Canadian company with its lead drug candidate in a Phase 3 trial recently closed an offering that raised CA$10 million for future research, which has one analyst contemplating the potential for "3x upside."
A San Diego-based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year.
Now that the FDA has lifted its clinical hold on Phase 3 study of Inovio Pharmaceutical's immunotherapy for cervical dysplasia, three analysts are making note of what the progress means for both the company and investors.
The potential of RXi Pharmaceuticals' sd-rxRNA technology in the development of cancer immunotherapies has resulted in an extension of its research collaboration with Oslo-based PCI Biotech and captured the attention of two analysts.
|"We continue to be positive about DRRX's story."|
|"VIVE raised its outlook for 2017 revenues from $14M to $15–16M."|
|"As of Q3/17E, PMN had $3.3M in cash and zero debt on its balance sheet; we are maintaining our Speculative Buy rating."|